320 related articles for article (PubMed ID: 24414704)
1. Age-related epigenetic drift in the pathogenesis of MDS and AML.
Maegawa S; Gough SM; Watanabe-Okochi N; Lu Y; Zhang N; Castoro RJ; Estecio MR; Jelinek J; Liang S; Kitamura T; Aplan PD; Issa JP
Genome Res; 2014 Apr; 24(4):580-91. PubMed ID: 24414704
[TBL] [Abstract][Full Text] [Related]
2. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
3. AML1 mutations induced MDS and MDS/AML in a mouse BMT model.
Watanabe-Okochi N; Kitaura J; Ono R; Harada H; Harada Y; Komeno Y; Nakajima H; Nosaka T; Inaba T; Kitamura T
Blood; 2008 Apr; 111(8):4297-308. PubMed ID: 18192504
[TBL] [Abstract][Full Text] [Related]
4. SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS.
Chen BY; Song J; Hu CL; Chen SB; Zhang Q; Xu CH; Wu JC; Hou D; Sun M; Zhang YL; Liu N; Yu PC; Liu P; Zong LJ; Zhang JY; Dai RF; Lan F; Huang QH; Zhang SJ; Nimer SD; Chen Z; Chen SJ; Sun XJ; Wang L
Blood; 2020 Jun; 135(25):2271-2285. PubMed ID: 32202636
[TBL] [Abstract][Full Text] [Related]
5. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.
Jiang Y; Dunbar A; Gondek LP; Mohan S; Rataul M; O'Keefe C; Sekeres M; Saunthararajah Y; Maciejewski JP
Blood; 2009 Feb; 113(6):1315-25. PubMed ID: 18832655
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic changes in therapy-related MDS/AML.
Voso MT; D'Alò F; Greco M; Fabiani E; Criscuolo M; Migliara G; Pagano L; Fianchi L; Guidi F; Hohaus S; Leone G
Chem Biol Interact; 2010 Mar; 184(1-2):46-9. PubMed ID: 19874806
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide methylation sequencing identifies progression-related epigenetic drivers in myelodysplastic syndromes.
Zhou JD; Zhang TJ; Xu ZJ; Deng ZQ; Gu Y; Ma JC; Wen XM; Leng JY; Lin J; Chen SN; Qian J
Cell Death Dis; 2020 Nov; 11(11):997. PubMed ID: 33219204
[TBL] [Abstract][Full Text] [Related]
8. Molecular bases of myelodysplastic syndromes: lessons from animal models.
Komeno Y; Kitaura J; Kitamura T
J Cell Physiol; 2009 Jun; 219(3):529-34. PubMed ID: 19259975
[TBL] [Abstract][Full Text] [Related]
9. [Research progress on mechanism of MDS transformation into AML].
Wang LL; Gao C; Chen BA
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):254-9. PubMed ID: 21362264
[TBL] [Abstract][Full Text] [Related]
10. NUP98-HOX translocations lead to myelodysplastic syndrome in mice and men.
Slape C; Lin YW; Hartung H; Zhang Z; Wolff L; Aplan PD
J Natl Cancer Inst Monogr; 2008; (39):64-8. PubMed ID: 18648006
[TBL] [Abstract][Full Text] [Related]
11. Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.
Babushok DV; Bessler M; Olson TS
Leuk Lymphoma; 2016; 57(3):520-36. PubMed ID: 26693794
[TBL] [Abstract][Full Text] [Related]
12. Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies.
Ye Y; McDevitt MA; Guo M; Zhang W; Galm O; Gore SD; Karp JE; Maciejewski JP; Kowalski J; Tsai HL; Gondek LP; Tsai HC; Wang X; Hooker C; Smith BD; Carraway HE; Herman JG
Cancer Res; 2009 Nov; 69(21):8482-90. PubMed ID: 19826047
[TBL] [Abstract][Full Text] [Related]
13. Aberrant DNA methylation impacts HOX genes expression in bone marrow mesenchymal stromal cells of myelodysplastic syndromes and de novo acute myeloid leukemia.
Roux B; Picou F; Debeissat C; Koubi M; Gallay N; Hirsch P; Ravalet N; Béné MC; Maigre M; Hunault M; Mosser J; Etcheverry A; Gyan E; Delhommeau F; Domenech J; Herault O
Cancer Gene Ther; 2022 Aug; 29(8-9):1263-1275. PubMed ID: 35194200
[TBL] [Abstract][Full Text] [Related]
14. Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome.
Xu F; Liu L; Chang CK; He Q; Wu LY; Zhang Z; Shi WH; Guo J; Zhu Y; Zhao YS; Gu SC; Fei CM; Li X
Oncotarget; 2016 Feb; 7(7):8119-30. PubMed ID: 26812882
[TBL] [Abstract][Full Text] [Related]
15. Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions.
Benetatos L; Dasoula A; Hatzimichael E; Syed N; Voukelatou M; Dranitsaris G; Bourantas KL; Crook T
Ann Hematol; 2011 Sep; 90(9):1037-45. PubMed ID: 21340720
[TBL] [Abstract][Full Text] [Related]
16. Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation.
Sashida G; Harada H; Matsui H; Oshima M; Yui M; Harada Y; Tanaka S; Mochizuki-Kashio M; Wang C; Saraya A; Muto T; Hayashi Y; Suzuki K; Nakajima H; Inaba T; Koseki H; Huang G; Kitamura T; Iwama A
Nat Commun; 2014 Jun; 5():4177. PubMed ID: 24953053
[TBL] [Abstract][Full Text] [Related]
17. Genetic predisposition syndromes: when should they be considered in the work-up of MDS?
Babushok DV; Bessler M
Best Pract Res Clin Haematol; 2015 Mar; 28(1):55-68. PubMed ID: 25659730
[TBL] [Abstract][Full Text] [Related]
18. Point mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome.
Harada H; Harada Y
Crit Rev Eukaryot Gene Expr; 2005; 15(3):183-96. PubMed ID: 16390315
[TBL] [Abstract][Full Text] [Related]
19. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.
Harada Y; Harada H
J Cell Biochem; 2011 Feb; 112(2):425-32. PubMed ID: 21268063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
